Clinical trial • Phase I • Oncology

Clinical trial in Advanced solid tumor

Phase I trial for Advanced solid tumor. None/Not specified-controlled. 105 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Advanced solid tumor
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
22-08-2024
First CTIS Authorization Date
05-02-2025

Trial design

None/Not specified-controlled Phase I trial across 3 sites in Belgium, Netherlands, France.

Comparator
None/Not specified
Target Sample Size
105

Recruitment

Planned Sample Size
105
Recruitment Window Months
52

Geography

Total Number Of Sites
3
Total Number Of Participants
45

Belgium

Earliest CTIS Part Ii Submission Date
12-11-2024
Latest Decision Or Authorization Date
21-08-2025
Processing Time Days
282
Number Of Sites
1
Number Of Participants
8

Sites

Site Name
UZ Leuven
Department Name
Medical oncology
Principal Investigator Name
Patrick Schöffski
Principal Investigator Email
patrick.schoffski@uzleuven.be
Contact Person Name
Patrick Schöffski
Contact Person Email
patrick.schoffski@uzleuven.be
Number Of Participants
8

Netherlands

Earliest CTIS Part Ii Submission Date
25-11-2024
Latest Decision Or Authorization Date
22-08-2025
Processing Time Days
270
Number Of Sites
1
Number Of Participants
9

Sites

Site Name
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Department Name
Clinical Research Unit, Department of Medical Oncology
Principal Investigator Name
Neeltje Steeghs
Principal Investigator Email
n.steeghs@nki.nl
Contact Person Name
Neeltje Steeghs
Contact Person Email
n.steeghs@nki.nl
Number Of Participants
9

France

Earliest CTIS Part Ii Submission Date
16-10-2024
Latest Decision Or Authorization Date
21-08-2025
Processing Time Days
309
Number Of Sites
1
Number Of Participants
28

Sites

Site Name
Centre Leon Berard
Department Name
Cancérologie médicale
Principal Investigator Name
Jean-Yves BLAY
Principal Investigator Email
jean-yves.blay@unicancer.fr
Contact Person Name
Jean-Yves BLAY
Contact Person Email
jean-yves.blay@unicancer.fr
Number Of Participants
28

Sponsor

Primary sponsor

Full Name
Daiichi Sankyo Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Related trials

Other published trials that may interest you.